Article Details
Retrieved on: 2021-03-31 14:48:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Kesimpta, as a second-to-market anti-CD20 therapy for MS, will directly compete with Roche's Ocrevus (ocrelizumab), which is well established on the ...
Article found on: www.pharmaceutical-technology.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here